Skip to main content
Clinical Trials/NCT01798433
NCT01798433
Completed
Not Applicable

A Prospective, Multi-center, Randomized Study to Evaluate the Optimal Strategy for Side Branch Treatment in Patients With Left Main Coronary Bifurcation Lesion

Samsung Medical Center1 site in 1 country200 target enrollmentMarch 18, 2013

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Coronary Artery Disease
Sponsor
Samsung Medical Center
Enrollment
200
Locations
1
Primary Endpoint
Target lesion failure
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

In patients with unprotected left main (LM) true bifurcation lesion (cohort A), elective 2-stent strategy is superior to provisional strategy at preventing the occurrence of 12-month target lesion failure after percutaneous coronary intervention for bifurcation lesion.

In patients with unprotected LM non-true bifurcation lesion (cohort B), 1-stent technique with mandatory final kissing ballooning is superior to 1-stent technique without kissing ballooning at preventing the occurrence of 12-month target lesion failure after percutaneous coronary intervention for bifurcation lesion.

Registry
clinicaltrials.gov
Start Date
March 18, 2013
End Date
July 31, 2018
Last Updated
7 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Hyeon-Cheol Gwon

Professor

Samsung Medical Center

Eligibility Criteria

Inclusion Criteria

  • Age ≥20 years
  • Left main bifurcation lesion on coronary angiography
  • Significant myocardial ischemia Main vessel (left main coronary artery and left anterior descending artery) and/or side branch (left circumflex artery) diameter stenosis \> 75%, or diameter stenosis 50-75% with angina and/or objective evidence of ischemia in the non-invasive stress test
  • Significant size of the main branch (left anterior descending artery) and side branch (left cirmflex artery) - The reference diameter of both branches ≥ 2.5 mm by visual estimation

Exclusion Criteria

  • The patient has a known hypersensitivity or contraindication to any of the following medications: Heparin, Aspirin, Clopidogrel, Biolimus
  • Patients who have received DES implantation in the target lesion prior to enrollment

Outcomes

Primary Outcomes

Target lesion failure

Time Frame: 12-month

defined ad a composite of cardiac death, spontaneous MI or target lesion revascularization

Secondary Outcomes

  • Cardiac death(12-month)
  • Angiographic in-segment restenosis rate(9 months)
  • Target vessel revascularization (TVR)(12-month)
  • Stent thrombosis(12-month)
  • Myocardial infarction (MI)(12-month)
  • Target lesion revascularization (TLR)(12-month)
  • Periprocedural CK-MB elevation(the first 48 hours after PCI)
  • Procedure success rate(the first 48 hours after PCI)
  • Procedure time(immediate after PCI)
  • Amount of contrast dye(immediate after PCI)

Study Sites (1)

Loading locations...

Similar Trials